Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -21676.57% is 593% below its 5-year average of 4395.25%, near the low end of its 5-year range (-23384.88%–93433.33%).
113.16% below its 12-month average of -10169.32%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -5764.52%.
EBITDA MARGIN
-21676.57%
EBITDA MARGIN AVG TTM
-10169.32%
EBITDA MARGIN AVG 3Y
-10169.32%
EBITDA MARGIN AVG 5Y
4395.25%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-113.16%
CURRENT VS 3Y AVG
-113.16%
CURRENT VS 5Y AVG
-593.18%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Pulse Biosciences, Inc.
Market Cap
$3.42B
EBITDA Margin
-21676.57%
TTM Avg
-10169.32%
3Y Avg
-10169.32%
5Y Avg
4395.25%
Market Cap
$3.44B
EBITDA Margin
-70.74%
TTM Avg
-2343.52%
3Y Avg
-1340.84%
5Y Avg
-951.82%
Market Cap
$3.38B
EBITDA Margin
10.88%
TTM Avg
18.32%
3Y Avg
-3.89%
5Y Avg
-19.05%
Market Cap
$3.51B
EBITDA Margin
-4940.36%
TTM Avg
-4940.36%
3Y Avg
-3147.19%
5Y Avg
-1703.30%
Market Cap
$3.52B
EBITDA Margin
-1.38%
TTM Avg
-8.27%
3Y Avg
-15.09%
5Y Avg
-16.30%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulse Biosciences, Inc. (PLSE) | $3.42B | -21676.57% | -10169.32% | -10169.32% | 4395.25% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.44B | -70.74% | -2343.52% | -1340.84% | -951.82% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 10.88% | 18.32% | -3.89% | -19.05% |
| Celcuity Inc. (CELC)vs › | $3.47B | N/A | N/A | N/A | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.34B | N/A | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.34B | -1.23% | 8.45% | -16.90% | -13.40% |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.51B | -4940.36% | -4940.36% | -3147.19% | -1703.30% |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | N/A | N/A | N/A | N/A |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | -1.38% | -8.27% | -15.09% | -16.30% |
| Veracyte, Inc. (VCYT)vs › | $3.55B | 18.48% | 13.68% | 1.79% | -7.31% |
Gross Margin
-360.0%
EBITDA Margin
-21676.6%
Operating Margin
-21982.6%
Net Margin
-6755.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -5764.52% |
| 2026-03-31 | -4711.97% |
| 2025-12-31 | -6815.91% |
| 2025-09-30 | -23384.88% |
| 2022-12-31 | 93433.33% |
| 2022-06-30 | -5154.72% |
| 2022-03-31 | -3816.89% |
| 2021-12-31 | -1790.64% |
| 2021-09-30 | -2436.59% |
